Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.

The global Factor VIII Deficiency Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.

This report aims to provide a comprehensive presentation of the global market for Factor VIII Deficiency Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Factor VIII Deficiency Treatment.

Report Scope

The Factor VIII Deficiency Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Factor VIII Deficiency Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Factor VIII Deficiency Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Factor VIII Deficiency Treatment Market Report

Report Metric	Details
Report Name	Factor VIII Deficiency Treatment Market
Segment by Type	Hemophilia A Drugs Hemophilia A Inhibitors Treatment Von Willebrand Disease Treatment
Segment by Application	Hospitals Clinics Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Takeda, Bayer HealthCare, CSL, Grifols, Novo Nordisk, F. Hoffmann-La Roche, Kedrion, Octapharma, Biogen Idec, BioMarin Pharmaceutical, Sangamo Therapeutics, Spark Therapeutics, Swedish Orphan Biovitrum, Uniqure NV, Amarna Therapeutics, Dimension Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Factor VIII Deficiency Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Factor VIII Deficiency Treatment Market report?

Ans: The main players in the Factor VIII Deficiency Treatment Market are Pfizer, Takeda, Bayer HealthCare, CSL, Grifols, Novo Nordisk, F. Hoffmann-La Roche, Kedrion, Octapharma, Biogen Idec, BioMarin Pharmaceutical, Sangamo Therapeutics, Spark Therapeutics, Swedish Orphan Biovitrum, Uniqure NV, Amarna Therapeutics, Dimension Therapeutics

What are the Application segmentation covered in the Factor VIII Deficiency Treatment Market report?

Ans: The Applications covered in the Factor VIII Deficiency Treatment Market report are Hospitals, Clinics, Other

What are the Type segmentation covered in the Factor VIII Deficiency Treatment Market report?

Ans: The Types covered in the Factor VIII Deficiency Treatment Market report are Hemophilia A Drugs, Hemophilia A Inhibitors Treatment, Von Willebrand Disease Treatment

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Factor VIII Deficiency Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Hemophilia A Drugs

1.2.3 Hemophilia A Inhibitors Treatment

1.2.4 Von Willebrand Disease Treatment

1.3 Market by Application

1.3.1 Global Factor VIII Deficiency Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Factor VIII Deficiency Treatment Market Perspective (2019-2030)

2.2 Factor VIII Deficiency Treatment Growth Trends by Region

2.2.1 Global Factor VIII Deficiency Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Factor VIII Deficiency Treatment Historic Market Size by Region (2019-2024)

2.2.3 Factor VIII Deficiency Treatment Forecasted Market Size by Region (2025-2030)

2.3 Factor VIII Deficiency Treatment Market Dynamics

2.3.1 Factor VIII Deficiency Treatment Industry Trends

2.3.2 Factor VIII Deficiency Treatment Market Drivers

2.3.3 Factor VIII Deficiency Treatment Market Challenges

2.3.4 Factor VIII Deficiency Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Factor VIII Deficiency Treatment Players by Revenue

3.1.1 Global Top Factor VIII Deficiency Treatment Players by Revenue (2019-2024)

3.1.2 Global Factor VIII Deficiency Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Factor VIII Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Factor VIII Deficiency Treatment Revenue

3.4 Global Factor VIII Deficiency Treatment Market Concentration Ratio

3.4.1 Global Factor VIII Deficiency Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Factor VIII Deficiency Treatment Revenue in 2023

3.5 Factor VIII Deficiency Treatment Key Players Head office and Area Served

3.6 Key Players Factor VIII Deficiency Treatment Product Solution and Service

3.7 Date of Enter into Factor VIII Deficiency Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Factor VIII Deficiency Treatment Breakdown Data by Type

4.1 Global Factor VIII Deficiency Treatment Historic Market Size by Type (2019-2024)

4.2 Global Factor VIII Deficiency Treatment Forecasted Market Size by Type (2025-2030)

5 Factor VIII Deficiency Treatment Breakdown Data by Application

5.1 Global Factor VIII Deficiency Treatment Historic Market Size by Application (2019-2024)

5.2 Global Factor VIII Deficiency Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Factor VIII Deficiency Treatment Market Size (2019-2030)

6.2 North America Factor VIII Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Factor VIII Deficiency Treatment Market Size by Country (2019-2024)

6.4 North America Factor VIII Deficiency Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Factor VIII Deficiency Treatment Market Size (2019-2030)

7.2 Europe Factor VIII Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Factor VIII Deficiency Treatment Market Size by Country (2019-2024)

7.4 Europe Factor VIII Deficiency Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Factor VIII Deficiency Treatment Market Size (2019-2030)

8.2 Asia-Pacific Factor VIII Deficiency Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Factor VIII Deficiency Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Factor VIII Deficiency Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Factor VIII Deficiency Treatment Market Size (2019-2030)

9.2 Latin America Factor VIII Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Factor VIII Deficiency Treatment Market Size by Country (2019-2024)

9.4 Latin America Factor VIII Deficiency Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Factor VIII Deficiency Treatment Market Size (2019-2030)

10.2 Middle East & Africa Factor VIII Deficiency Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Factor VIII Deficiency Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Factor VIII Deficiency Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Factor VIII Deficiency Treatment Introduction

11.1.4 Pfizer Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 Takeda

11.2.1 Takeda Company Detail

11.2.2 Takeda Business Overview

11.2.3 Takeda Factor VIII Deficiency Treatment Introduction

11.2.4 Takeda Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.2.5 Takeda Recent Development

11.3 Bayer HealthCare

11.3.1 Bayer HealthCare Company Detail

11.3.2 Bayer HealthCare Business Overview

11.3.3 Bayer HealthCare Factor VIII Deficiency Treatment Introduction

11.3.4 Bayer HealthCare Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.3.5 Bayer HealthCare Recent Development

11.4 CSL

11.4.1 CSL Company Detail

11.4.2 CSL Business Overview

11.4.3 CSL Factor VIII Deficiency Treatment Introduction

11.4.4 CSL Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.4.5 CSL Recent Development

11.5 Grifols

11.5.1 Grifols Company Detail

11.5.2 Grifols Business Overview

11.5.3 Grifols Factor VIII Deficiency Treatment Introduction

11.5.4 Grifols Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.5.5 Grifols Recent Development

11.6 Novo Nordisk

11.6.1 Novo Nordisk Company Detail

11.6.2 Novo Nordisk Business Overview

11.6.3 Novo Nordisk Factor VIII Deficiency Treatment Introduction

11.6.4 Novo Nordisk Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.6.5 Novo Nordisk Recent Development

11.7 F. Hoffmann-La Roche

11.7.1 F. Hoffmann-La Roche Company Detail

11.7.2 F. Hoffmann-La Roche Business Overview

11.7.3 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Introduction

11.7.4 F. Hoffmann-La Roche Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.7.5 F. Hoffmann-La Roche Recent Development

11.8 Kedrion

11.8.1 Kedrion Company Detail

11.8.2 Kedrion Business Overview

11.8.3 Kedrion Factor VIII Deficiency Treatment Introduction

11.8.4 Kedrion Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.8.5 Kedrion Recent Development

11.9 Octapharma

11.9.1 Octapharma Company Detail

11.9.2 Octapharma Business Overview

11.9.3 Octapharma Factor VIII Deficiency Treatment Introduction

11.9.4 Octapharma Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.9.5 Octapharma Recent Development

11.10 Biogen Idec

11.10.1 Biogen Idec Company Detail

11.10.2 Biogen Idec Business Overview

11.10.3 Biogen Idec Factor VIII Deficiency Treatment Introduction

11.10.4 Biogen Idec Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.10.5 Biogen Idec Recent Development

11.11 BioMarin Pharmaceutical

11.11.1 BioMarin Pharmaceutical Company Detail

11.11.2 BioMarin Pharmaceutical Business Overview

11.11.3 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Introduction

11.11.4 BioMarin Pharmaceutical Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.11.5 BioMarin Pharmaceutical Recent Development

11.12 Sangamo Therapeutics

11.12.1 Sangamo Therapeutics Company Detail

11.12.2 Sangamo Therapeutics Business Overview

11.12.3 Sangamo Therapeutics Factor VIII Deficiency Treatment Introduction

11.12.4 Sangamo Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.12.5 Sangamo Therapeutics Recent Development

11.13 Spark Therapeutics

11.13.1 Spark Therapeutics Company Detail

11.13.2 Spark Therapeutics Business Overview

11.13.3 Spark Therapeutics Factor VIII Deficiency Treatment Introduction

11.13.4 Spark Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.13.5 Spark Therapeutics Recent Development

11.14 Swedish Orphan Biovitrum

11.14.1 Swedish Orphan Biovitrum Company Detail

11.14.2 Swedish Orphan Biovitrum Business Overview

11.14.3 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Introduction

11.14.4 Swedish Orphan Biovitrum Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.14.5 Swedish Orphan Biovitrum Recent Development

11.15 Uniqure NV

11.15.1 Uniqure NV Company Detail

11.15.2 Uniqure NV Business Overview

11.15.3 Uniqure NV Factor VIII Deficiency Treatment Introduction

11.15.4 Uniqure NV Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.15.5 Uniqure NV Recent Development

11.16 Amarna Therapeutics

11.16.1 Amarna Therapeutics Company Detail

11.16.2 Amarna Therapeutics Business Overview

11.16.3 Amarna Therapeutics Factor VIII Deficiency Treatment Introduction

11.16.4 Amarna Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.16.5 Amarna Therapeutics Recent Development

11.17 Dimension Therapeutics

11.17.1 Dimension Therapeutics Company Detail

11.17.2 Dimension Therapeutics Business Overview

11.17.3 Dimension Therapeutics Factor VIII Deficiency Treatment Introduction

11.17.4 Dimension Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024)

11.17.5 Dimension Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

BioMarin Pharmaceutical

Sangamo Therapeutics

Spark Therapeutics

Swedish Orphan Biovitrum

Uniqure

Amarna Therapeutics

Dimension Therapeutics

Novo Nordisk

List of Tables

Table 1. Global Factor VIII Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Hemophilia A Drugs

Table 3. Key Players of Hemophilia A Inhibitors Treatment

Table 4. Key Players of Von Willebrand Disease Treatment

Table 5. Global Factor VIII Deficiency Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Factor VIII Deficiency Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Factor VIII Deficiency Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Factor VIII Deficiency Treatment Market Share by Region (2019-2024)

Table 9. Global Factor VIII Deficiency Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Factor VIII Deficiency Treatment Market Share by Region (2025-2030)

Table 11. Factor VIII Deficiency Treatment Market Trends

Table 12. Factor VIII Deficiency Treatment Market Drivers

Table 13. Factor VIII Deficiency Treatment Market Challenges

Table 14. Factor VIII Deficiency Treatment Market Restraints

Table 15. Global Factor VIII Deficiency Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Factor VIII Deficiency Treatment Market Share by Players (2019-2024)

Table 17. Global Top Factor VIII Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Factor VIII Deficiency Treatment as of 2023)

Table 18. Ranking of Global Top Factor VIII Deficiency Treatment Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Factor VIII Deficiency Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Factor VIII Deficiency Treatment Product Solution and Service

Table 22. Date of Enter into Factor VIII Deficiency Treatment Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Factor VIII Deficiency Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Factor VIII Deficiency Treatment Revenue Market Share by Type (2019-2024)

Table 26. Global Factor VIII Deficiency Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Factor VIII Deficiency Treatment Revenue Market Share by Type (2025-2030)

Table 28. Global Factor VIII Deficiency Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Factor VIII Deficiency Treatment Revenue Market Share by Application (2019-2024)

Table 30. Global Factor VIII Deficiency Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Factor VIII Deficiency Treatment Revenue Market Share by Application (2025-2030)

Table 32. North America Factor VIII Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Factor VIII Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Factor VIII Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Factor VIII Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Factor VIII Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Factor VIII Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Factor VIII Deficiency Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Factor VIII Deficiency Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Factor VIII Deficiency Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Factor VIII Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Factor VIII Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Factor VIII Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Factor VIII Deficiency Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Factor VIII Deficiency Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Factor VIII Deficiency Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 47. Pfizer Company Detail

Table 48. Pfizer Business Overview

Table 49. Pfizer Factor VIII Deficiency Treatment Product

Table 50. Pfizer Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Takeda Company Detail

Table 53. Takeda Business Overview

Table 54. Takeda Factor VIII Deficiency Treatment Product

Table 55. Takeda Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 56. Takeda Recent Development

Table 57. Bayer HealthCare Company Detail

Table 58. Bayer HealthCare Business Overview

Table 59. Bayer HealthCare Factor VIII Deficiency Treatment Product

Table 60. Bayer HealthCare Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 61. Bayer HealthCare Recent Development

Table 62. CSL Company Detail

Table 63. CSL Business Overview

Table 64. CSL Factor VIII Deficiency Treatment Product

Table 65. CSL Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 66. CSL Recent Development

Table 67. Grifols Company Detail

Table 68. Grifols Business Overview

Table 69. Grifols Factor VIII Deficiency Treatment Product

Table 70. Grifols Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 71. Grifols Recent Development

Table 72. Novo Nordisk Company Detail

Table 73. Novo Nordisk Business Overview

Table 74. Novo Nordisk Factor VIII Deficiency Treatment Product

Table 75. Novo Nordisk Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 76. Novo Nordisk Recent Development

Table 77. F. Hoffmann-La Roche Company Detail

Table 78. F. Hoffmann-La Roche Business Overview

Table 79. F. Hoffmann-La Roche Factor VIII Deficiency Treatment Product

Table 80. F. Hoffmann-La Roche Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 81. F. Hoffmann-La Roche Recent Development

Table 82. Kedrion Company Detail

Table 83. Kedrion Business Overview

Table 84. Kedrion Factor VIII Deficiency Treatment Product

Table 85. Kedrion Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 86. Kedrion Recent Development

Table 87. Octapharma Company Detail

Table 88. Octapharma Business Overview

Table 89. Octapharma Factor VIII Deficiency Treatment Product

Table 90. Octapharma Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 91. Octapharma Recent Development

Table 92. Biogen Idec Company Detail

Table 93. Biogen Idec Business Overview

Table 94. Biogen Idec Factor VIII Deficiency Treatment Product

Table 95. Biogen Idec Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 96. Biogen Idec Recent Development

Table 97. BioMarin Pharmaceutical Company Detail

Table 98. BioMarin Pharmaceutical Business Overview

Table 99. BioMarin Pharmaceutical Factor VIII Deficiency Treatment Product

Table 100. BioMarin Pharmaceutical Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 101. BioMarin Pharmaceutical Recent Development

Table 102. Sangamo Therapeutics Company Detail

Table 103. Sangamo Therapeutics Business Overview

Table 104. Sangamo Therapeutics Factor VIII Deficiency Treatment Product

Table 105. Sangamo Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 106. Sangamo Therapeutics Recent Development

Table 107. Spark Therapeutics Company Detail

Table 108. Spark Therapeutics Business Overview

Table 109. Spark Therapeutics Factor VIII Deficiency Treatment Product

Table 110. Spark Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 111. Spark Therapeutics Recent Development

Table 112. Swedish Orphan Biovitrum Company Detail

Table 113. Swedish Orphan Biovitrum Business Overview

Table 114. Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Product

Table 115. Swedish Orphan Biovitrum Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 116. Swedish Orphan Biovitrum Recent Development

Table 117. Uniqure NV Company Detail

Table 118. Uniqure NV Business Overview

Table 119. Uniqure NV Factor VIII Deficiency Treatment Product

Table 120. Uniqure NV Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 121. Uniqure NV Recent Development

Table 122. Amarna Therapeutics Company Detail

Table 123. Amarna Therapeutics Business Overview

Table 124. Amarna Therapeutics Factor VIII Deficiency Treatment Product

Table 125. Amarna Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 126. Amarna Therapeutics Recent Development

Table 127. Dimension Therapeutics Company Detail

Table 128. Dimension Therapeutics Business Overview

Table 129. Dimension Therapeutics Factor VIII Deficiency Treatment Product

Table 130. Dimension Therapeutics Revenue in Factor VIII Deficiency Treatment Business (2019-2024) & (US$ Million)

Table 131. Dimension Therapeutics Recent Development

Table 132. Research Programs/Design for This Report

Table 133. Key Data Information from Secondary Sources

Table 134. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Factor VIII Deficiency Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Factor VIII Deficiency Treatment Market Share by Type: 2023 VS 2030

Figure 3. Hemophilia A Drugs Features

Figure 4. Hemophilia A Inhibitors Treatment Features

Figure 5. Von Willebrand Disease Treatment Features

Figure 6. Global Factor VIII Deficiency Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Factor VIII Deficiency Treatment Market Share by Application: 2023 VS 2030

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Other Case Studies

Figure 11. Factor VIII Deficiency Treatment Report Years Considered

Figure 12. Global Factor VIII Deficiency Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Factor VIII Deficiency Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Factor VIII Deficiency Treatment Market Share by Region: 2023 VS 2030

Figure 15. Global Factor VIII Deficiency Treatment Market Share by Players in 2023

Figure 16. Global Top Factor VIII Deficiency Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Factor VIII Deficiency Treatment as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Factor VIII Deficiency Treatment Revenue in 2023

Figure 18. North America Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Factor VIII Deficiency Treatment Market Share by Country (2019-2030)

Figure 20. United States Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Factor VIII Deficiency Treatment Market Share by Country (2019-2030)

Figure 24. Germany Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Factor VIII Deficiency Treatment Market Share by Region (2019-2030)

Figure 32. China Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Factor VIII Deficiency Treatment Market Share by Country (2019-2030)

Figure 40. Mexico Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Factor VIII Deficiency Treatment Market Share by Country (2019-2030)

Figure 44. Turkey Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Factor VIII Deficiency Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Pfizer Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 47. Takeda Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 48. Bayer HealthCare Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 49. CSL Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 50. Grifols Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 51. Novo Nordisk Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 52. F. Hoffmann-La Roche Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 53. Kedrion Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 54. Octapharma Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 55. Biogen Idec Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 56. BioMarin Pharmaceutical Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 57. Sangamo Therapeutics Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 58. Spark Therapeutics Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 59. Swedish Orphan Biovitrum Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 60. Uniqure NV Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 61. Amarna Therapeutics Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 62. Dimension Therapeutics Revenue Growth Rate in Factor VIII Deficiency Treatment Business (2019-2024)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions